![Stephen R. Donahue](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen R. Donahue
Nessuna posizione attualmente
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Oren M. Becker | M | - |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Mark Gabrielson | M | 68 | 3 anni | |
James Fordyce | M | 81 | 1 anni | |
Ben Palleiko | M | 58 | 1 anni | |
Fredrick Frank | M | 92 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | 5 anni |
David L. Urdal | M | 74 | 3 anni | |
Ian Smith | M | 58 |
Predix Pharmaceuticals, Inc.
![]() Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | 1 anni |
Julian Adams | M | 69 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Michael Kauffman | M | 60 |
Predix Pharmaceuticals, Inc.
![]() Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | 4 anni |
Kimberlee Drapkin | F | 56 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | 1 anni |
David Collier | M | 61 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Christine H. Wang | F | - |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Yigal Erlich | M | 84 |
Predix Pharmaceuticals Holdings, Inc.
![]() Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 13 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Stephen R. Donahue
- Contatti personali